APAstrid Petersmann

Astrid Petersmann

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Astrid Petersmann has a total of 193 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The DZHK research platform: maximisation of scientific value by enabling access to health data and biological samples collected in cardiovascular clinical studies

    by Julia Hoffmann, Sabine Hanß, Monika Kraus, Jens Schaller, Christian Schäfer, Dana Stahl, Stefan D. Anker, Gabriele Anton, Thomas Bahls, Stefan Blankenberg, et al.

    The German Centre for Cardiovascular Research (DZHK) is one of the German Centres for Health Research and aims to conduct early and guideline-relevant studies to develop new therapies and diagnostics that impact the lives of people with cardiovascular disease. Therefore, DZHK members designed a collaboratively organised and integrated research platform connecting all sites and partners. The overarching objectives of the research platform are the standardisation of prospective data and biological sample collections among all studies and the development of a sustainable centrally standardised storage in compliance with general legal regulations and the FAIR principles. The main elements of the DZHK infrastructure are web-based and central units for data management, LIMS, IDMS, and transfer office, embedded in a framework consisting of the DZHK Use and Access Policy, and the Ethics and Data Protection Concept. This framework is characterised by a modular design allowing a high standardisation across all studies. For studies that require even tighter criteria additional quality levels are defined. In addition, the Public Open Data strategy is an important focus of DZHK. The DZHK operates as one legal entity holding all rights of data and biological sample usage, according to the DZHK Use and Access Policy. All DZHK studies collect a basic set of data and biosamples, accompanied by specific clinical and imaging data and biobanking. The DZHK infrastructure was constructed by scientists with the focus on the needs of scientists conducting clinical studies. Through this, the DZHK enables the interdisciplinary and multiple use of data and biological samples by scientists inside and outside the DZHK. So far, 27 DZHK studies recruited well over 11,200 participants suffering from major cardiovascular disorders such as myocardial infarction or heart failure. Currently, data and samples of five DZHK studies of the DZHK Heart Bank can be applied for.


  • Open Access

    Estimates of protection against SARS-CoV-2 infection and severe COVID-19 in Germany before the 2022/2023 winter season - the IMMUNEBRIDGE project

    by Berit Lange, Veronika K Jaeger, Manuela Harries, Viktoria Rücker, Hendrik Streeck, Sabine Blaschke, Astrid Petersmann, Nicole Toepfner, Matthias Nauck, Max J Hassenstein, et al.

    Despite the need to generate valid and reliable estimates of protection against SARS-CoV-2 infection and severe course of COVID-19 for the German population in summer 2022, there was a lack of systematically collected population-based data allowing for the assessment of the protection level in real-time. In the IMMUNEBRIDGE project, we harmonised data and biosamples for nine population-/hospital-based studies (total number of participants n=33,637) to provide estimates for protection levels against SARS-CoV-2 infection and severe COVID-19 between June and November 2022. Based on evidence synthesis, we formed a combined endpoint of protection levels based on the number of self-reported infections/vaccinations in combination with nucleocapsid/spike antibody responses (“confirmed exposures”). Four confirmed exposures represented the highest protection level, and no exposure represented the lowest. Most participants were seropositive against the spike antigen; 37% of the participants ≥79 years had less than four confirmed exposures (highest level of protection) and 5% less than three. In the subgroup of participants with comorbidities, 46-56% had less than four confirmed exposures. We found major heterogeneity across federal states, with 4%-28% of participants having less than three confirmed exposures. Using serological analyses, literature synthesis and infection dynamics during the survey period, we observed moderate to high levels of protection against severe COVID-19, whereas the protection against SARS-CoV-2 infection was low across all age groups. We found relevant protection gaps in the oldest age group and amongst individuals with comorbidities, indicating a need for additional protective measures in these groups.


  • Open Access

    Bridging the gap – estimation of 2022/2023 SARS-CoV-2 healthcare burden in Germany based on multidimensional data from a rapid epidemic panel

    by M Harries, V.K Jaeger, I Rodiah, M.J. Hassenstein, J Ortmann, M Dreier, I von Holt, M Brinkmann, A Dulovic, D Gornyk, et al.

    Throughout the SARS-CoV-2 pandemic, Germany lacked an adaptive population panel for epidemic diseases and a modelling platform to rapidly incorporate panel estimates. We evaluated how a cross-sectional analysis of 9922 participants of the MuSPAD study in June/July 2022 combined with a newly developed modelling platform could bridge the gap and analyzed antibody levels, neutralizing serum activity and interferon-gamma release response of serum samples. We categorized the population into four groups with differing protection against severe course of disease (validated by neutralizing serum activity), and found that 30% were in the group with highest protection, and 85% in either the highest categories or second highest group regarding protection level. Estimated hospitalizations due to SARS-CoV-2 were predicted to be between 30 to 300% of the peak in 02/2021 dependent on assumed variant characteristics. We showed the feasibility of a rapid epidemic panel able to evaluate complex endpoints for SARS-CoV-2 and inform scenario modelling.


  • Messqualität bei der Glukosemessung im Rahmen der Diabetesdiagnose und -therapie in Deutschland

    by Guido Freckmann, Lutz Heinemann, Stefan Pleus, Astrid Petersmann, Patricia Kaiser, Matthias Nauck

    Article published online: 20 June 2022 © 2022. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany


  • Disregarded Measurement Uncertainty Contributions and Their Magnitude in Measuring Plasma Glucose

    by Astrid Petersmann, Rainer Macdonald, Matthias Nauck

    Each measurement is subject to measurement uncertainty (MU). Consequently, each measurement of plasma glucose concentration used for diagnosis and monitoring of diabetes mellitus (DM) is affected. Although concepts and methods of MU are well established in many fields of science and technology, they are presently only incompletely implemented by medical laboratories, neglecting MU of target values of internal quality control (IQC) materials. An empirical and practical approach for the estimation of MU based on the analysis of routine IQC using control samples with assigned target values is presented. Its feasibility is demonstrated exemplarily by analyzing IQC data from one year obtained for glucose employing the hexokinase method with IQC of two different concentrations. Combined relative extended (k = 2) MU comprising bias, coefficient of variation (CV), and MU of the target values assigned to control materials were about 9% with a lower (~ 56 mg/dL; ~3.1 mmol/L) and 8% with a higher (~ 346 mg/dL; ~19.2 mmol/L) concentration sample, analyzing IQC of one year from three different devices. Estimation of MU in this study is quite reliable due to the large number of IQC data from one year. The MU of the target values of the commercial control material in this study was considerably larger than other MU contributions, ie, standard deviation and bias. In the future, the contribution of MU of commercial IQC should be addressed more carefully and technologies to measure glucose should be geared toward smaller MU possible, as needed, especially for glucose concentration measurements in diagnosis and management of DM.


  • Open Access

    The Integrated Research Biobank of the University Medicine Greifswald

    by Theresa Winter, Nele Friedrich, Sophia Lamp, Christian Schäfer, Mario Schattschneider, Stefan Bollmann, Diana Brümmer, Katja Riemann, Astrid Petersmann, Matthias Nauck

    The Integrated Research Biobank (IRB) at the Institute of Clinical Chemistry and Laboratory Medicine (IKCL) is the central biobank resource of the University Medicine Greifswald (UMG) for all biological materials collected within the framework of clinical and experimental studies carried out by internal and external researchers. The IRB is a core unit of the UMG and focuses on collection, processing and storage of mainly liquid biomaterials, e.g. blood, urine, saliva or swaps in established workflows and thereby securing highest quality standards. Aliquots are usually stored at –80°C in one of the two fully automated LiCONiC biorepositories or, if necessary, in one of the –80°C freezers. Up to now, the IRB stores more than 1.1 million liquid aliquots and the collection grows continuously. Currently, the storage capacity of the IRB is limited to 3 million aliquots. Funding statement: European Fond for Regional Development (EFRE) funded by the European Union (grant INZ-EFRE 1503).Study of Health in Pomerania (SHIP) is part of the Community Medicine Research net (CMR) of the University of Greifswald, Germany, which is funded by the Federal Ministry of Education and Research (grants no. 01ZZ9603, 01ZZ0103 and 01ZZ0403), the Ministry of Cultural Affairs as well as the Social Ministry of the Federal State of Mecklenburg-West Pomerania.German Centre for Cardiovascular Research (DZHK) funded by the Federal Ministry of Education and Research (grant 81Z7400173).German Biobank Alliance (GBA) funded by the Federal Ministry of Education and Research (grant 01EY1705).National Cohort (NAKO) funded by the Federal Ministry of Education and Research (grant 01ER1301/18).


  • Open Access

    Measurement Uncertainty Impacts Diagnosis of Diabetes Mellitus: Reliable Minimal Difference of Plasma Glucose Results

    by Sandra Keutmann, Stephanie Zylla, Mathilde Dahl, Nele Friedrich, Rüdiger Landgraf, Lutz Heinemann, Anders Kallner, Matthias Nauck, Astrid Petersmann

    Introduction The diagnosis of diabetes mellitus is based on suitable cut-off values of specific biomarkers, such as the concentration of glucose in plasma. The German Diabetes Association has very recently published a clinical practice guideline on the definition, classification and diagnosis of diabetes mellitus that recommends measurements of plasma glucose concentration have an imprecision defined as a minimal difference (MD) of at a fasting plasma glucose concentration of 7.0 mmol/L. To obtain reliable values for the MD, we investigated long-term and short-term measurement uncertainty. Methods The imprecision was determined by two approaches: (1) a long-term dataset with imprecision based on the Guideline of the German Medical Association on Quality Assurance in Medical Laboratory Examinations (Rili-BAEK), in a medical laboratory operating 24/7, using internal quality control (IQC) data for four concentrations during a 10-year period; and (2) a detailed short-term dataset with imprecision assessed by hourly measurements of control materials. These datasets were used to calculate the MD cut-off (MDcut-off) as: \( {\text{MD}}_{\text{cut-off}} = k \times {\text{SD}} \) = 2 \( \times {\text{SD}} \), where SD is the standard deviation and k = 2 represents a confidence level of 95%. Results The MDcut-off of ≤ 0.7 mmol/L at a fasting plasma glucose concentration of 7.0 mmol/L (MDcut-off 7.0) for the long-term and the short-term approaches were 0.44 and 0.40 mmol/L, respectively. The MDcut-off 7.0 from both approaches was therefore below the recommended value of 0.7 mmol/L. It was noted that the variability in performance within and between instruments can be covered by reporting the long-term MDcut-off 7.0 across all connected instruments. In this study, stable results for the MDcut-off 7.0 were obtained after 1 year. Conclusion Imprecision as measured by IQC data is remarkably stable over many years of operation. Current imprecision assessment usually focuses on only single instruments, whereas clinicians perceive the measurement as the result of the combined analytical performance of all instruments used for a certain assay. In the clinical setting, the MD may be a more useful measure of imprecision, and we suggest deriving the MDcut-off combined from all instruments and control cycles that are used in the patient care setting for a given analyte.


  • Open Access

    Definition, classification and diagnostics of diabetes mellitus

    by Astrid Petersmann, Matthias Nauck, Dirk Müller‐Wieland, W. Kerner, Ulrich Müller, Rüdiger Landgraf, Guido Freckmann, Lutz Heinemann

    This recommendation aims to provide up-to-date information and the latest consensus on diabetes diagnosis from a group of experts in Germany. The disease diabetes mellitus is classified and its different types are described briefly. Options for diagnosis are presented including current cut-off values as well as reference intervals to recognize glucose utilization disorders like impaired fasting glucose or impaired glucose tolerance. Special attention is paid to the measurement value imprecision. The minimal difference (MD) is introduced as an excellent measure to distinguish measurement results which are analytically different from each other. Potential caveats considering pre-analytics in glucose measurement and limitations of HbA1c assessment for diagnosis of diabetes mellitus are presented. Taken together, this recommendation provides a comprehensive overview of the state of the art in diabetes mellitus diagnosis and also critically evaluates potential pitfalls. The aim of recommendations like this one issued by the German Diabetes Association is to provide the diabetologist and his team the information he needs for his daily practice. These recommendations are updated annually. They are written by a group of experts, but they are not evidence-based guidelines. This specific recommendation for diabetes diagnosis briefly describes the diabetes types and the different options for diagnosis. Also the caveats and the practical procedure are presented.


  • Extending laboratory automation to the wards: effect of an innovative pneumatic tube system on diagnostic samples and transport time

    by Juliane Suchsland, Theresa Winter, Anne Greiser, Thomas Streichert, Benjamin Otto, Julia Mayerle, Sören Runge, Anders Kallner, Matthias Nauck, Astrid Petersmann

    Background: The innovative pneumatic tube system (iPTS) transports one sample at a time without the use of cartridges and allows rapid sending of samples directly into the bulk loader of a laboratory automation system (LAS). We investigated effects of the iPTS on samples and turn-around time (TAT). Methods: During transport, a mini data logger recorded the accelerations in three dimensions and reported them in arbitrary area under the curve (AUC) units. In addition representative quantities of clinical chemistry, hematology and coagulation were measured and compared in 20 blood sample pairs transported by iPTS and courier. Results: Samples transported by iPTS were brought to the laboratory (300 m) within 30 s without adverse effects on the samples. The information retrieved from the data logger showed a median AUC of 7 and 310 arbitrary units for courier and iPTS transport, respectively. This is considerably below the reported limit for noticeable hemolysis of 500 arbitrary units. Conclusions: iPTS reduces TAT by reducing the hands-on time and a fast transport. No differences in the measurement results were found for any of the investigated 36 analytes between courier and iPTS transport. Based on these findings the iPTS was cleared for clinical use in our hospital.


  • Tolerance of platelet concentrates treated with UVC‐light only for pathogen reduction – a phase I clinical trial

    by T. Thiele, P. Pohler, T. Kohlmann, A. Sümnig, K. Aurich, K. Selleng, A. Westphal, T. Bakchoul, A. Petersmann, T. H. Müller, et al.

    Background: The THERAFLEX UV‐Platelets pathogen reduction system for platelet concentrates (PCs) operates with ultraviolet C light (UVC; 254 nm) only without addition of photosensitizers. This phase I study evaluated safety and tolerability of autologous UVC‐irradiated PCs in healthy volunteers.Methods: Eleven volunteers underwent two single (series 1 and 2) and one double apheresis (series 3). PCs were treated with UVC, stored for 48 h and retransfused in a dose‐escalation scheme: 12·5, 25% and 50% of a PC (series 1); one complete PC (series 2); two PCs (series 3). Platelet counts, fibrinogen, activated partial thromboplastin time, prothrombin time, D‐dimer, standard haematology, temperature, heart rate, blood pressure and clinical chemistry parameters were measured. One‐ and 24‐h corrected count increments were determined in series 2 and 3. Platelet‐specific antibodies were assessed before and at the end of the study.Results: Neither adverse reactions related to transfusions nor antibodies against UVC‐treated platelets were observed. Corrected count increments did not differ between series 2 and 3.Conclusions: Repeated transfusions of autologous UVC‐treated PCs were well tolerated and did not induce antibody responses in all volunteers studied. EudraCT No. 2010‐023404‐26.